Skip to main content

Table 1 Clinical characteristics of donor and mutation load in the 5 PDOs

From: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

 CRC-01CRC-03CRC-04CRC-05CRC-08
Age at biopsy (years)6061595251
Sexmalefemalefemalemalemale
StageIVIVIVIVIV
Prior chemotherapyYesYesYesYesNo
Non-silent mutation load2081068918078
APCp.Y935X, p.S1411 fsp.R876Xp.S1356Xp.Q1367Xp.Y1075fs
TP53 p.G245Sp.T284 fsp.R210Xp.R205C
KRASp.G12CAmplificationp.A18Dp.G12Dp.G12D
TCF7L2 p.F105 fs   
SMAD4  p.G365R